Nöromüsküler Hastalıkların Rehabilitasyonu
Özet
Nöromüsküler hastalıklar; ön boynuz motor hücreleri, periferik sinirler, nöromüsküler kavşak ve iskelet kas liflerindeki anormallikler sonucu ortaya çıkan, ilerleyici kas kuvvet kaybı ve fonksiyonel azalmayla karakterize geniş bir spektrumu kapsar. Bu hastalıkların rehabilitasyonunda temel amaç; fiziksel, duygusal ve sosyal yetenekleri geri kazandırarak yaşam kalitesini artırmaktır. Motor nöron hastalıklarından ALS'de palyatif ve multidisipliner yaklaşımlar ön plandayken, SMA ve Post-Poliomiyelit sendromunda kas kuvvetini korumak ve kontraktürleri önlemek hedeflenir. Guillain-Barré Sendromu ve CIDP gibi periferik sinir hastalıklarında aşamalı fizik tedavi programları ve mobilizasyon kritik öneme sahiptir. Nöromüsküler kavşak hastalıklarından Myastenia Gravis'te solunum kas eğitimi ve aerobik aktiviteler kondisyonsuzlaşmayı önlemede faydalıdır. Miyopatilerde ise immünosupresif tedavi ile kombine edilen bireysel egzersizler kas kütlesi kaybını engeller. Genel rehabilitasyon stratejileri; kişiye özgü planlanan hafif-orta şiddette direnç egzersizlerini, germe aktivitelerini, pulmoner rehabilitasyonu, su içi egzersizleri ve ağrı kontrol yöntemlerini içerir. Ancak yüksek dirençli eksantrik egzersizler kas liflerine zarar verebileceğinden kaçınılmalıdır. Sonuç olarak, bu ilerleyici süreçte fonksiyonel kapasitenin korunması multidisipliner bir ekip çalışmasını zorunlu kılmaktadır.
Neuromuscular diseases encompass a broad spectrum of disorders arising from abnormalities in anterior horn motor cells, peripheral nerves, the neuromuscular junction, and skeletal muscle fibers, characterized by progressive muscle weakness and functional decline. The primary objective of rehabilitation in these diseases is to improve the quality of life by restoring physical, emotional, and social capabilities. While palliative and multidisciplinary approaches are prominent in ALS, a motor neuron disease, the focus in SMA and Post-Poliomyelitis syndrome is on maintaining muscle strength and preventing contractures. Gradual physical therapy programs and mobilization are critically important in peripheral nerve diseases such as Guillain-Barré Syndrome and CIDP. In Myasthenia Gravis, a neuromuscular junction disorder, respiratory muscle training and aerobic activities help prevent deconditioning. For myopathies, individualized exercises combined with immunosuppressive therapy prevent the loss of muscle mass. General rehabilitation strategies include customized mild-to-moderate resistance exercises, stretching activities, pulmonary rehabilitation, aquatic exercises, and pain management. However, high-resistance eccentric exercises should be avoided as they can damage muscle fibers. Consequently, preserving functional capacity in this progressive process necessitates a multidisciplinary team effort.
Referanslar
Lehmann, H., Köller, H., & Hartung, H. (2014). Neuromuscular rehabilitation: Diseases of the motor neuron, peripheral nerve, neuromuscular junction, and the muscle,Textbook of Neural Repair and Rehabilitation (pp. 655-673). Cambridge: Cambridge University doi:10.1017/CBO9780511995590.052
Simmons Z, Bremer BA, Robbins RA, et al. Quality of life in ALS depends on factors other than strength and physical function. Neurology 2000; 55: 388–92.
Shibata M, Abe K, Jimbo A, et al. Complex regional pain syndrome type I associated with amyotrophic lateral sclerosis. Clin J Pain 2003; 19: 69–70.
Bertelsen M, Broberg S, Madsen E. Outcome of physiotherapy as part of a multidisciplinary rehabilitation in an unselected polio population with oneyear follow-up: an uncontrolled study. J Rehabil Med 2009; 41: 85–7.
Ho TW, McKhann GM, Griffin JW. Human autoimmune neuropathies. Annu Rev Neurosci 1988; 21: 187–226.
Hughes RA, Swan AV, Raphaël JC, et al. Immunotherapy for Guillain–Barré syndrome: a systematic review. Brain 2007; 130: 2245–57
El Mhandi L, Calmels P, Camdessanché JP, et al. Muscle strength recovery in treated Guillain–Barré syndrome: a prospective study for the first 18 months after onset. Am J Phys Med Rehabil 2007; 86: 716–24
Newsom-Davis J. Lambert–Eaton myasthenic syndrome. Rev Neurol (Paris) 2004; 160: 177–80
Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 2011; 7: 297–306.
Zink W, Kollmar R, Schwab S. Critical illness polyneuropathy and myopathy in the intensive care unit. Nat Rev Neurol 2009; 5: 372–9.
Needham DM, Truong AD, Fan E. Technology to enhance physical rehabilitation of critically ill patients. Crit Care Med 2009; 37: S436–41
Demir, Yasemin Parlak. “Neuromuscular Diseases and Rehabilitation.” (2017).
Abresch RT, et al. Exercise in neuromuscular diseases. Physical Medicine and Rehabilitation Clinics of North America 2012; 23(3): 653–73.
Fowler WM. Role of physical activity and exercise training in neuromuscular diseases. American Journal of Physical Medicine and Rehabilitation. 2002; 81: 187–95.
Kılınç M (2016). Nöromusküler hastalıklar, Fizyoterapi ve Rehabilitasyon,Cilt 3, Bölüm 4, ss 49–61 Hipokrat Kitabevi (Ankara), Pelikan Kitabevi (Ankara),Nisan Kitabevi (Eskisehir), 2016.
Kang SW, Bach JR. Maximum insufflation capacity: vital capacity and cough flows in neuromuscular disease. American Journal of Physical Medicine and Rehabilitation. 2000; 79(3): 222–7.
Parlak DY. The effects of different walk aids on energy expenditure, risk of falling and gait parameters in patients with adult neuromuscular diseases. Hacettepe University, Health Sciences, Physiotherapy and rehabilitation Doctoral Thesis, Ankara, 2015.
Favier FB, Benoit H, Freyssenet D. Cellular and molecular events controlling skeletal muscle mass in response to altered use. Pflugers Arch. 2008; 456:587–600
Kilmer DD. Response to resistive strengthening exercise training in humans with neuromuscular disease. Am J Phys Med Rehabil 2002;81(Suppl):S121–S126.
Anziska Y, Sternberg A. Exercise in neuromuscular disease. Muscle Nerve. 2013 Jul;48(1):3-20. doi: 10.1002/mus.23771.
Lou JS, Weiss MD, Carter GC. Assessment and management of fatigue in neuromuscular disease. Am J Hosp Palliat Care 2010;27:145– 157.
